-Treatment effects were evaluated by mixed-meal tolerance test (MMTT) and, for all except pasireotide, by 6 days of continuous glucose monitoring (CGM).-Acarbose and pasireotide significantly increased nadir glucose levels and reduced time in hypoglycemia during MMTTs.-Acarbose decreased peak glucose levels, whereas pasireotide increased both peak glucose and time in hyperglycemia.-Verapamil and liraglutide had no significant impact on hypoglycemia.-Pasireotide significantly diminished glucagon-like peptide-1 (GLP-1) levels. The gene discussed is GCG; the disease is Hypoglycemia.